Strides Optimistic On Prospects Of Antiviral Portfolio For COVID-19

Favipiravir Bioequivalence Studies To Begin In India

Optimistic about the potential of repurposing its antiviral portfolio, Strides plans to soon begin bioequivalence studies for favipiravir, a molecule that has found favor as a COVID-19 therapy in a few countries. It also aims to introduce new products to fill the gap left by the withdrawal of ranitidine from the US market.

Antivirals
Will Strides' Antivirals Find Use As COVID-19 Therapy? • Source: Shutterstock

Adopting a strategy that lives up to the tagline ‘Reset, Resurgent’ that its investor presentations begins with, Strides Pharma Science Ltd. plans to repurpose some existing medicines for COVID-19 while counting on new products to fill the gap in revenues left by ranitidine after its withdrawal from the US market this April post a request by the US Food and Drug Administration (FDA).

During the fourth quarter to March, Strides reported marginally higher consolidated revenues of INR6.36bn ($83.8m) versus INR6.33bn for the same...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip